---

Highlights for June 2018

1. Cipla partners with Eli Lilly to market Lilly’s insulin glargine injection, Basaglar, in India.
2. Lupin has tied up with Japan’s Nichi-Iko for the distribution, promotion and sale of Lupin’s recently filed biosimilar Etanercept in Japan.
3. Ferring Pharma to expand in India by investing US$250 Million in R&D and Manufacturing infrastructure.
4. Cipla and Unitaid have struck a landmark agreement to lower the price of the first combination therapy that prevents opportunistic infections in people living with HIV.
5. Lupin teams up with Mylan to sell arthritis drug Enbrel in select geographies.
6. Oxford BioMedica and Axovant Sciences enter into a US$842.5 Million Exclusive Worldwide Licence Agreement for the Treatment of Parkinson’s Disease.
7. Korean companies OCI and Bukwang Pharmaceuticals establish a 50:50 JV. 
8. Biogen inks US$357 Million Exclusive Option deal for TMS’ Phase 2 stroke drug.
9. Genentech signs US$534 Million deal with Microbiotica to search gut bacteria for IBD targets, new drugs.
10. Fresenius inks US$150 Million deal to bring Humacyte’s blood vessel implant to its dialysis clinics.
11. Recipharm to buy Sanofi inhalation contract business and plant in U.K. for US$60 Million.
12. Zai Lab and Crescendo Biologics enter exclusive worldwide license agreement for Innovative Protein Therapeutics for inflammatory indications.
13. Sanofi, Translate Bio ink mRNA vaccine R&D deal worth up to US$805 Million.

Updates at Aagami: 

• Aagami completed a fruitful BIO International Convention in Boston, MA on 04-07 June, 2018 with 50+ one-to-one partnering meetings.
• Aagami CEO to visit Korea and Japan in August 2018 for striking strategic alliances.